Biotron Ltd (BIT) - Total Liabilities
Based on the latest financial reports, Biotron Ltd (BIT) has total liabilities worth AU$1.16 Million AUD (≈ $821.73K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Biotron Ltd (BIT) cash flow conversion to assess how effectively this company generates cash.
Biotron Ltd - Total Liabilities Trend (2000–2025)
This chart illustrates how Biotron Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Biotron Ltd (BIT) asset resilience to evaluate the company's liquid asset resilience ratio.
Biotron Ltd Competitors by Total Liabilities
The table below lists competitors of Biotron Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chenghe Acquisition II Co.
NYSE MKT:CHEB
|
USA | $6.90 Million |
|
Zenvia Inc
NASDAQ:ZENV
|
USA | $930.11 Million |
|
Star Fashion Culture Holdings Limited
NASDAQ:STFS
|
USA | $41.42 Million |
|
NCC Group plc
LSE:NCC
|
UK | GBX136.80 Million |
|
Binect AG
XETRA:MA10
|
Germany | €3.31 Million |
|
Polar Power Inc
NASDAQ:POLA
|
USA | $9.52 Million |
|
Global Sukses Solusi Tbk PT
JK:RUNS
|
Indonesia | Rp22.59 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Biotron Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Biotron Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotron Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotron Ltd (2000–2025)
The table below shows the annual total liabilities of Biotron Ltd from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$428.51K ≈ $303.20K |
-41.90% |
| 2024-06-30 | AU$737.51K ≈ $521.83K |
-23.38% |
| 2023-06-30 | AU$962.49K ≈ $681.03K |
+18.31% |
| 2022-06-30 | AU$813.57K ≈ $575.65K |
+75.52% |
| 2021-06-30 | AU$463.51K ≈ $327.96K |
-45.67% |
| 2020-06-30 | AU$853.19K ≈ $603.69K |
+104.11% |
| 2019-06-30 | AU$418.00K ≈ $295.76K |
+23.78% |
| 2018-06-30 | AU$337.70K ≈ $238.95K |
-45.49% |
| 2017-06-30 | AU$619.51K ≈ $438.34K |
+78.89% |
| 2016-06-30 | AU$346.32K ≈ $245.04K |
-26.81% |
| 2015-06-30 | AU$473.18K ≈ $334.80K |
-0.31% |
| 2014-06-30 | AU$474.64K ≈ $335.84K |
+21.37% |
| 2013-06-30 | AU$391.08K ≈ $276.71K |
+103.50% |
| 2012-06-30 | AU$192.18K ≈ $135.98K |
-21.34% |
| 2011-06-30 | AU$244.32K ≈ $172.87K |
+74.16% |
| 2010-06-30 | AU$140.29K ≈ $99.26K |
-36.90% |
| 2009-06-30 | AU$222.33K ≈ $157.31K |
-47.56% |
| 2008-06-30 | AU$423.94K ≈ $299.97K |
+160.05% |
| 2007-06-30 | AU$163.02K ≈ $115.35K |
-48.75% |
| 2006-06-30 | AU$318.11K ≈ $225.08K |
+112.24% |
| 2005-06-30 | AU$149.88K ≈ $106.05K |
-2.25% |
| 2004-06-30 | AU$153.33K ≈ $108.49K |
+3.55% |
| 2003-06-30 | AU$148.08K ≈ $104.77K |
+3.63% |
| 2002-06-30 | AU$142.90K ≈ $101.11K |
+28.22% |
| 2001-06-30 | AU$111.45K ≈ $78.86K |
+406.59% |
| 2000-06-30 | AU$22.00K ≈ $15.57K |
-- |
About Biotron Ltd
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 for the treatment of SARS-CoV-2, HIV-1, hepatitis C virus, hepatitis B virus (HBV), influenza, and dengue virus infections. The company was incorporated in 1999 and is based in Sydney, Australia.